BRPI0918360A2 - composto, composição farmacêutica e usos de um composto - Google Patents

composto, composição farmacêutica e usos de um composto

Info

Publication number: BRPI0918360A2
Authority: BR; Brazil
Prior art keywords: compound; pharmaceutical composition; pharmaceutical; composition
Prior art date: 2008-12-19

Application number

BRPI0918360A

Other languages

English (en)

Inventor

J Souers Andrew

M Petros Andrew

Edmund Sleebs Brad

John Smith Brian

Thien Bui Chinh

Ndubaku Chudi

A Dudley Danette

Nikolakopoulos George

Laurent Lessene Guillaume

A Flygare John

Bayldon Baell Jonathan

Geoffrey Watson Keith

Deshayes Kurt

Wang Le

A Hasvold Lisa

Colman Peter

Czabotar Peter

W Elmore Steven

J Fairbrother Wayne

Wang Xilu

Tao Zhi-Fu

Original Assignee

Abbott Lab

Genentech Inc

Walter & Eliza Hall Inst Medical Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-19

Filing date

2009-12-17

Publication date

2017-10-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42316723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0918360(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-17 Application filed by Abbott Lab, Genentech Inc, Walter & Eliza Hall Inst Medical Res filed Critical Abbott Lab

2017-10-10 Publication of BRPI0918360A2 publication Critical patent/BRPI0918360A2/pt

2017-12-05 Publication of BRPI0918360A8 publication Critical patent/BRPI0918360A8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/06—Peri-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BRPI0918360A 2008-12-19 2009-12-17 Composto, composição farmacêutica e usos de um composto BRPI0918360A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13949208P	2008-12-19	2008-12-19
PCT/US2009/068496 WO2010080503A1 (en)	2008-12-19	2009-12-17	Heterocyclic compounds and methods of use

Publications (2)

Publication Number	Publication Date
BRPI0918360A2 true BRPI0918360A2 (pt)	2017-10-10
BRPI0918360A8 BRPI0918360A8 (pt)	2017-12-05

Family

ID=42316723

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0918360A BRPI0918360A8 (pt)	2008-12-19	2009-12-17	Composto, composição farmacêutica e usos de um composto

Country Status (22)

Country	Link
US (1)	US8232273B2 (pt)
EP (1)	EP2373163B1 (pt)
JP (1)	JP5770102B2 (pt)
KR (1)	KR101685718B1 (pt)
CN (1)	CN102316733B (pt)
AU (1)	AU2009335843A1 (pt)
BR (1)	BRPI0918360A8 (pt)
CA (1)	CA2747170C (pt)
CL (1)	CL2011001485A1 (pt)
CO (1)	CO6390075A2 (pt)
CR (1)	CR20110388A (pt)
DO (1)	DOP2011000199A (pt)
EC (1)	ECSP11011213A (pt)
ES (1)	ES2544452T3 (pt)
IL (1)	IL213596A0 (pt)
MX (1)	MX2011006509A (pt)
NZ (1)	NZ593537A (pt)
PE (1)	PE20120334A1 (pt)
RU (1)	RU2525116C2 (pt)
SG (1)	SG172259A1 (pt)
WO (1)	WO2010080503A1 (pt)
ZA (1)	ZA201104467B (pt)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2682354C (en)	2007-04-16	2016-12-13	Abbott Laboratories	7-nonsubstituted indole mcl-1 inhibitors
ES2462715T3 (es) *	2008-12-19	2014-05-26	Genentech, Inc.	Compuestos y métodos de uso
US8628554B2 (en)	2010-06-13	2014-01-14	Virender K. Sharma	Intragastric device for treating obesity
US10420665B2 (en)	2010-06-13	2019-09-24	W. L. Gore & Associates, Inc.	Intragastric device for treating obesity
US9526648B2 (en)	2010-06-13	2016-12-27	Synerz Medical, Inc.	Intragastric device for treating obesity
US10010439B2 (en)	2010-06-13	2018-07-03	Synerz Medical, Inc.	Intragastric device for treating obesity
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EA023030B1 (ru) *	2011-05-20	2016-04-29	Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед	Новые соединения в качестве ингибиторов диацилглицеролацилтрансферазы
US8940737B2 (en)	2011-10-14	2015-01-27	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN103987711B (zh)	2011-10-14	2016-08-24	艾伯维公司	作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
TWI561521B (en) *	2011-10-14	2016-12-11	Abbvie Inc	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) *	2011-10-14	2017-02-21	艾伯維有限公司	用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
JP5955531B2 (ja) *	2011-11-07	2016-07-20	千葉県	抗癌剤
SI2861595T1 (sl)	2012-06-13	2017-04-26	Incyte Holdings Corporation	Substituirane triciklične spojine kot inhibitorji fgfr
CN103515415A (zh) *	2012-06-26	2014-01-15	群康科技(深圳)有限公司	叠层结构与其制造方法、以及包含其的电子装置
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
MX360172B (es) *	2012-08-13	2018-10-12	Abbvie Inc	Agentes que inducen la apoptosis.
JP6318156B2 (ja) *	2012-09-06	2018-04-25	プレキシコンインコーポレーテッドＰｌｅｘｘｉｋｏｎＩｎｃ．	キナーゼをモジュレートするための化合物および方法、ならびにその指標
SG11201501314TA (en) *	2012-10-11	2015-03-30	Hoffmann La Roche	Azaindolines
US9796729B2 (en)	2012-11-23	2017-10-24	Glaxosmithkline Llc	Compounds as diacylglycerol acyltransferase inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
WO2014145852A2 (en)	2013-03-15	2014-09-18	Knopp Biosciences Llc	Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
ES2657451T3 (es)	2013-04-19	2018-03-05	Incyte Holdings Corporation	Heterocíclicos bicíclicos como inhibidores del FGFR
FR3008979B1 (fr) *	2013-07-23	2015-07-24	Servier Lab	Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008975A1 (fr)	2013-07-23	2015-01-30	Servier Lab	Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN112274641A (zh)	2014-01-28	2021-01-29	巴克老龄化研究所	用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物
US11331328B2 (en)	2014-05-05	2022-05-17	Bioventures, Llc	Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
AU2015292710A1 (en)	2014-07-22	2017-02-16	Bioventures, Llc.	Compositions and methods for selectively depleting senescent cells
LT3572405T (lt)	2014-09-12	2023-10-25	Biohaven Therapeutics Ltd.	Benzoimidazol-1,2-ilo amidai, kaip kv7 kanalų aktyvatoriai
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
CN107223123A (zh) *	2014-12-09	2017-09-29	艾伯维公司	具有低细胞渗透性的bcl‑xl抑制性化合物以及包括它的抗体药物缀合物
AU2015360621A1 (en) *	2014-12-09	2017-06-29	Abbvie Inc.	Bcl-xL inhibitory compounds and antibody drug conjugates including the same
WO2016131100A1 (en) *	2015-02-18	2016-08-25	The Walter And Eliza Hall Institute Of Medical Research	Methods of treating infectious diseases
CA2976790C (en)	2015-02-20	2024-02-27	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10195213B2 (en)	2015-03-13	2019-02-05	Unity Biotechnology, Inc.	Chemical entities that kill senescent cells for use in treating age-related disease
WO2016172218A1 (en) *	2015-04-20	2016-10-27	The Regents Of The University Of Michigan	Small molecule inhibitors of mcl-1 and uses thereof
MX2018002631A (es)	2015-09-03	2019-02-07	Univ Arizona	Inhibidores de molecula pequeña de dyrkia y usos de los mismos.
WO2017087318A1 (en) *	2015-11-20	2017-05-26	Mingsight Pharmaceuticals, Inc.	Treatment of autoimmune disease
WO2017184995A1 (en)	2016-04-21	2017-10-26	Bioventures, Llc	Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
US10779980B2 (en)	2016-04-27	2020-09-22	Synerz Medical, Inc.	Intragastric device for treating obesity
ES2861499T3 (es)	2016-06-08	2021-10-06	Abbvie Inc	Anticuerpos anti-B7-H3 y conjugados anticuerpo-fármaco
US11833203B2 (en) *	2016-08-09	2023-12-05	University Of Durham	Synthetic retinoids (in cell modulation)
AR109596A1 (es)	2016-09-09	2018-12-26	Incyte Corp	Compuestos pirazolopiridina y sus usos
US20180072718A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
WO2018049152A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018092064A1 (en) *	2016-11-18	2018-05-24	Novartis Ag	Combinations of mdm2 inhibitors and bcl-xl inhibitors
US20180228786A1 (en)	2017-02-15	2018-08-16	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019051199A1 (en)	2017-09-08	2019-03-14	Incyte Corporation	6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
CN108186642B (zh) *	2018-01-11	2019-11-08	广西师范大学	一种协同起作用治疗肺癌的药物组合物
CN112105360B (zh)	2018-01-22	2024-01-30	生物风险投资有限责任公司	用于癌症治疗的bcl-2蛋白降解剂
US10752635B2 (en)	2018-02-20	2020-08-25	Incyte Corporation	Indazole compounds and uses thereof
US10745388B2 (en)	2018-02-20	2020-08-18	Incyte Corporation	Indazole compounds and uses thereof
LT3755703T (lt)	2018-02-20	2022-10-10	Incyte Corporation	N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui
US12528810B2 (en)	2018-03-01	2026-01-20	Arizona Board Of Regents On Behalf Of The University Of Arizona	Small molecule inhibitors of DYRK/CLK and uses thereof
CN118955401A (zh)	2018-03-19	2024-11-15	诺普生物科学有限责任公司	Kv7通道激活剂组合物和使用方法
US11299473B2 (en)	2018-04-13	2022-04-12	Incyte Corporation	Benzimidazole and indole compounds and uses thereof
KR20210018265A (ko)	2018-05-04	2021-02-17	인사이트 코포레이션	Fgfr 억제제의 고체 형태 및 이의 제조 방법
MX2020011639A (es)	2018-05-04	2021-02-15	Incyte Corp	Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
WO2019221755A1 (en)	2018-05-18	2019-11-21	Bioventures, Llc	Piperlongumine analogues and uses thereof
US10899755B2 (en)	2018-08-08	2021-01-26	Incyte Corporation	Benzothiazole compounds and uses thereof
EP3856348B1 (en)	2018-09-25	2024-01-03	Incyte Corporation	Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
AR119494A1 (es) *	2019-07-29	2021-12-22	Servier Lab	DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
US11066394B2 (en)	2019-08-06	2021-07-20	Incyte Corporation	Solid forms of an HPK1 inhibitor
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
JP7675711B2 (ja)	2019-10-14	2025-05-13	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021113479A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
CR20220285A (es)	2019-12-04	2022-10-27	Incyte Corp	Derivados de un inhibidor de fgfr
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CN112079791A (zh) *	2020-08-21	2020-12-15	宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室）	单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
EP4251209A1 (en)	2020-11-24	2023-10-04	Novartis AG	Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
AR124681A1 (es)	2021-01-20	2023-04-26	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
CN117794929A (zh)	2021-02-02	2024-03-29	法国施维雅药厂	选择性bcl-xl protac化合物及使用方法
JP2024513575A (ja)	2021-04-12	2024-03-26	インサイト・コーポレイション	Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
KR102605163B1 (ko) *	2021-06-01	2023-11-23	연세대학교 산학협력단	뇌암의 예방 또는 치료용 조성물
EP4352060A1 (en)	2021-06-09	2024-04-17	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr
CN114294905B (zh) *	2021-11-19	2023-04-25	中粮生物科技股份有限公司	利用红外或微波干燥聚羟基脂肪酸酯的方法
CA3256012A1 (en)	2022-05-20	2023-11-23	Les Laboratoires Servier	ANTIBODY-DRUG CONJUGATES, MET INHIBITORS BCL-XL, AND THEIR METHODS OF USE
WO2023225359A1 (en)	2022-05-20	2023-11-23	Novartis Ag	Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
EP4525925A1 (en)	2022-05-20	2025-03-26	Novartis AG	Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
EP4574175A1 (en) *	2022-08-19	2025-06-25	Beijing Suncell Bio-Medical Co., Ltd.	Prodrug for anti-aging related diseases and use method therefor
WO2025111431A1 (en)	2023-11-22	2025-05-30	Les Laboratoires Servier	Anti-cd7 antibody-drug conjugates and methods of use thereof
WO2025111450A1 (en)	2023-11-22	2025-05-30	Les Laboratoires Servier	Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025130875A1 (zh) *	2023-12-18	2025-06-26	南京瑞初医药有限公司	氮杂环化合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3718570A1 (de) *	1987-06-03	1988-12-15	Boehringer Ingelheim Kg	Benzo- und thieno-3,4-dihydro-1- pyridinylessigsaeurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
AU2001249399A1 (en) *	2000-03-24	2001-10-08	Cor Therapeutics, Inc.	Isoquinolone inhibitors of factor xa
NZ523839A (en) *	2000-08-01	2005-07-29	Ono Pharmaceutical Co	3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient
AU2003249713A1 (en) *	2002-07-03	2004-01-23	Axys Pharmaceuticals, Inc.	3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
CA2539546C (en) *	2003-09-23	2010-07-13	Merck & Co., Inc.	Isoquinoline potassium channel inhibitors
US7767684B2 (en) *	2003-11-13	2010-08-03	Abbott Laboratories	Apoptosis promoters
KR101389246B1 (ko) *	2004-07-15	2014-04-24	브리스톨-마이어스스퀴브컴파니	아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
US7297700B2 (en) *	2005-03-24	2007-11-20	Renovis, Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
ES2389062T3 (es) *	2006-01-18	2012-10-22	Amgen, Inc	Compuestos de tiazol como inhibidores de proteína cinasa B (PKB)
JP4968860B2 (ja) *	2006-10-31	2012-07-04	シェーリングコーポレイション	アニリノピペラジン誘導体およびアニリノピペラジン誘導体を使用する方法
US8338455B2 (en) *	2006-12-20	2012-12-25	Amgen Inc.	Compounds and methods of use
US8653091B2 (en) *	2007-04-02	2014-02-18	Evotec Ag	Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof
CA2682356C (en) *	2007-04-16	2016-06-14	Abbott Laboratories	7-substituted indole mcl-1 inhibitors
CA2682354C (en) *	2007-04-16	2016-12-13	Abbott Laboratories	7-nonsubstituted indole mcl-1 inhibitors
RU2474580C2 (ru) *	2007-07-19	2013-02-10	Шеринг Корпорейшн	Гетероциклические амидные соединения как ингибиторы протеинкиназ
CN101842362A (zh) *	2007-09-27	2010-09-22	沃尔特及伊莱萨霍尔医学研究院	苯并噻唑化合物
ES2462715T3 (es) *	2008-12-19	2014-05-26	Genentech, Inc.	Compuestos y métodos de uso

2009
- 2009-12-17 NZ NZ593537A patent/NZ593537A/xx not_active IP Right Cessation
- 2009-12-17 BR BRPI0918360A patent/BRPI0918360A8/pt not_active Application Discontinuation
- 2009-12-17 CA CA2747170A patent/CA2747170C/en not_active Expired - Fee Related
- 2009-12-17 RU RU2011129776/04A patent/RU2525116C2/ru active
- 2009-12-17 AU AU2009335843A patent/AU2009335843A1/en not_active Abandoned
- 2009-12-17 US US12/641,141 patent/US8232273B2/en active Active
- 2009-12-17 JP JP2011542439A patent/JP5770102B2/ja active Active
- 2009-12-17 SG SG2011044856A patent/SG172259A1/en unknown
- 2009-12-17 PE PE2011001254A patent/PE20120334A1/es not_active Application Discontinuation
- 2009-12-17 ES ES09837920.9T patent/ES2544452T3/es active Active
- 2009-12-17 WO PCT/US2009/068496 patent/WO2010080503A1/en not_active Ceased
- 2009-12-17 EP EP09837920.9A patent/EP2373163B1/en active Active
- 2009-12-17 KR KR1020117016722A patent/KR101685718B1/ko not_active Expired - Fee Related
- 2009-12-17 MX MX2011006509A patent/MX2011006509A/es active IP Right Grant
- 2009-12-17 CN CN200980156732.7A patent/CN102316733B/zh active Active
2011
- 2011-06-15 ZA ZA2011/04467A patent/ZA201104467B/en unknown
- 2011-06-16 IL IL213596A patent/IL213596A0/en unknown
- 2011-06-17 CL CL2011001485A patent/CL2011001485A1/es unknown
- 2011-06-20 DO DO2011000199A patent/DOP2011000199A/es unknown
- 2011-07-06 CO CO11084232A patent/CO6390075A2/es active IP Right Grant
- 2011-07-18 EC EC2011011213A patent/ECSP11011213A/es unknown
- 2011-07-18 CR CR20110388A patent/CR20110388A/es unknown

Also Published As

Publication number	Publication date
DOP2011000199A (es)	2011-10-15
SG172259A1 (en)	2011-07-28
EP2373163B1 (en)	2015-06-10
AU2009335843A1 (en)	2011-07-21
EP2373163A4 (en)	2012-10-24
ES2544452T3 (es)	2015-08-31
CR20110388A (es)	2011-09-09
US20100210622A1 (en)	2010-08-19
CA2747170A1 (en)	2010-07-15
CO6390075A2 (es)	2012-02-29
JP5770102B2 (ja)	2015-08-26
ZA201104467B (en)	2012-10-31
RU2525116C2 (ru)	2014-08-10
NZ593537A (en)	2013-07-26
IL213596A0 (en)	2011-07-31
WO2010080503A1 (en)	2010-07-15
PE20120334A1 (es)	2012-04-16
KR20110102473A (ko)	2011-09-16
US8232273B2 (en)	2012-07-31
ECSP11011213A (es)	2011-09-30
CL2011001485A1 (es)	2012-02-24
MX2011006509A (es)	2011-10-19
RU2011129776A (ru)	2013-01-27
CN102316733B (zh)	2014-01-01
BRPI0918360A8 (pt)	2017-12-05
KR101685718B1 (ko)	2016-12-12
CA2747170C (en)	2017-07-18
EP2373163A1 (en)	2011-10-12
JP2012512891A (ja)	2012-06-07
CN102316733A (zh)	2012-01-11

Publication	Publication Date	Title
BRPI0918360A2 (pt)	2017-10-10	composto, composição farmacêutica e usos de um composto
BRPI1016219A2 (pt)	2016-04-26	composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt)	2016-03-08	composto, uso de um composto, e, composição farmacêutica
BRPI0919942A2 (pt)	2014-12-23	Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt)	2017-05-23	composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt)	2015-12-29	composto, composição farmacêutica, e, uso de um composto
BRPI1007018A2 (pt)	2016-03-29	composto, composição farmacêutica, e , uso de um composto.
BRPI1008906A2 (pt)	2016-03-15	composto, composição farmacêutica, e, uso de um composto.
BRPI0917579A2 (pt)	2016-10-11	composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0906962A2 (pt)	2015-07-14	Composto, e, composição farmacêutica
BRPI0906556A2 (pt)	2015-07-07	Composto, e, composição farmacêutica
BRPI1009372A2 (pt)	2016-05-31	compostos, composição farmacêutica e respectivos usos
BRPI0908021A2 (pt)	2015-07-21	Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BRPI0921879A2 (pt)	2018-10-16	composto, composição farmacêutica , e, uso de um composto
BRPI0810696A2 (pt)	2014-10-21	Composto, composição farmacêutica, e, uso de um composto
BR112013008259A2 (pt)	2017-12-12	composto, composição farmacêutica, e, uso de um composto
BR112013015397A2 (pt)	2016-09-20	composto, composição farmacêutica, e, uso de um composto
BRPI0917681A2 (pt)	2015-08-04	Composto, e, composição farmacêutica
BRPI0906937A2 (pt)	2016-04-19	composto, composição farmacêutica, e, uso de um composto
BRPI1009757A2 (pt)	2016-03-15	composto, composição farmacêutica, e , uso de um composto.
BRPI0915473A2 (pt)	2015-11-10	composto, composição farmacêutica, e, uso de um composto
DK2285413T3 (da)	2012-08-27	Farmaceutisk sammensætning
EP2236149A4 (en)	2012-12-26	MEDICAL COMPOSITION
BRPI0919165A2 (pt)	2015-12-08	composição farmacêutica,e, uso de um composto
BRPI0918517A2 (pt)	2015-12-01	composto, composição farmacêutica, e, uso de um composto

Legal Events

Date	Code	Title	Description
2017-12-05	B25A	Requested transfer of rights approved	Owner name: GENENTECH, INC. (US) , THE WALTER AND ELIZA HALL I
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-16	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-05-05	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-05-26	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-09-15	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements